ABSTRACT
INTRODUCTION
cancer cells both in vitro and in vivo (7, 9, 15, (19) (20) (21) . Strikingly, patients with high levels of reagent (Invitrogen) as described (27) . Reporter gene assay was performed as previously 128 described (28) with either an androgen-responsive element-luciferase plasmid (ARE-luc) 129 containing three ARE regions ligated in tandem to the luciferase reporter or a luciferase construct 130 driven by three repeats of an AR-V-specific promoter element of the ubiquitin-conjugating were obtained by using a Leica TCS SP2 system with a 40X oil-immersion objective on a Z- 
Statistical Analysis

179
The Student's two-tailed t test was used to determine the mean differences between two 180 groups. P < 0.05 is considered significant. Data are presented as mean ± SEM.
RESULTS
182
Characterization of AR-FL and AR-Vs in BiFC fusion proteins
183
For BiFC analysis of interaction between proteins A and B, the two proteins are fused and the dimerization did not require androgen ( Fig. 2A & 2B) . To delineate the dimerization interface, we generated mutant BiFC-AR-V constructs with mutations at the FxxLF motif 
Characterization of AR-FL and AR-Vs in BRET fusion proteins
238
We then used the newest BRET system, BRET6 (24), to confirm the BiFC results.
239
BRET6 is based on energy transfer between the Rluc8.6 Renilla luciferase (Rluc) energy donor 
androgen-independent manner could be equally important as their AR-FL-independent activity to 297 castration resistance.
299
We and others showed previously that AR-V7 and AR We reported previously that AR-V binds to the promoter of its specific target UBE2C 
